{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T23:55:01Z","timestamp":1784850901309,"version":"3.55.0"},"reference-count":84,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["437802\/2018-3"],"award-info":[{"award-number":["437802\/2018-3"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Checkpoint inhibitors have revolutionized advanced melanoma care; however, their cutaneous side effects have not been definitively elucidated.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Objective<\/jats:title>\n<jats:p>To identify the prevalence of cutaneous toxicity in patients with melanoma treated with immune checkpoint inhibitors as monotherapy and\/or in combination with chemotherapy and\/or radiotherapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Materials and methods<\/jats:title>\n<jats:p>We performed a systematic review and meta-analysis, which encompassed both clinical trials and observational studies describing the dermatological toxicities in patients treated with immune checkpoint inhibitors. The protocol was registered in the International Prospective Register of Systematic Review under the number CRD42018091915. The searches were performed using the CINAHL, Cochrane CENTRAL, LILACS, LIVIVO, PubMed, Scopus, and Web of Science databases. The methodological quality of the studies was evaluated with the JBI Critical Appraisal Checklist for Studies Reporting Prevalence Data<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 9,802 articles were identified in the databases. The final sample comprised 39 studies. The evaluated drugs were ipilimumab, tremelimumab, pembrolizumab, and nivolumab. The results suggest that the most prevalent side effect was grade 1 and 2 pruritus (24%), followed by grade 1 and 2 rash (21%) and grade 1 and 2 vitiligo (10%).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The most prevalent side effects in patients treated with checkpoint inhibitors are pruritus, rash, and vitiligo, and they are rated mostly as grades 1 and 2 adverse events. Remarkably, vitiligo is most commonly found in patients treated with PD-1 inhibitors.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0255716","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T17:36:12Z","timestamp":1628271372000},"page":"e0255716","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":32,"title":["Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4799-6880","authenticated-orcid":true,"given":"N\u00e1thali Fel\u00edcia","family":"Mineiro dos Santos Garrett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Cristina","family":"Carvalho da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Barros Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Elaine","family":"Diniz dos Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9586-9486","authenticated-orcid":true,"given":"Christiane","family":"Inoc\u00eancio Vasques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,8,6]]},"reference":[{"issue":"17","key":"pone.0255716.ref001","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.2217\/fon.15.118","article-title":"Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis.","volume":"11","author":"O Abdel-Rahman","year":"2015","journal-title":"Future Oncol."},{"issue":"6","key":"pone.0255716.ref002","doi-asserted-by":"crossref","first-page":"8541","DOI":"10.1002\/jcp.27816","article-title":"Immune checkpoint blockade opens a new way to cancer immunotherapy","volume":"234","author":"S Sadreddini","year":"2019","journal-title":"J Cell Physiol"},{"key":"pone.0255716.ref003","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1200\/EDBK_243071","article-title":"Frontline Therapy for BRAF-Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer?","volume":"39","author":"AC Pavlick","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book.Jan"},{"issue":"4","key":"pone.0255716.ref004","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"DM Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"pone.0255716.ref005","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1080\/1744666X.2017.1366315","article-title":"Immunotherapy of cancers comes of age","volume":"13","author":"H Yousefi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"issue":"19","key":"pone.0255716.ref006","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","article-title":"CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients","volume":"19","author":"PA Ott","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"3","key":"pone.0255716.ref007","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2217\/mmt.15.17","article-title":"Immune checkpoint inhibitors in melanoma.","volume":"2","author":"AJ Cooper","year":"2015","journal-title":"Melanoma Manag."},{"issue":"2","key":"pone.0255716.ref008","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.hoc.2018.12.008","article-title":"Immunotherapy toxicity.","volume":"33","author":"CM Mantia","year":"2019","journal-title":"Hematol Oncol Clin North Am."},{"issue":"2","key":"pone.0255716.ref009","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy.","volume":"44","author":"JL Curry","year":"2017","journal-title":"J Cutan Pathol."},{"key":"pone.0255716.ref010","first-page":"5036213","article-title":"Cutaneous side effects of targeted therapy and immunotherapy for advanced melanoma.","volume":"2018","author":"I Russo","year":"2018","journal-title":"Scientifica (Cairo)."},{"issue":"2","key":"pone.0255716.ref011","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"MA Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0255716.ref012","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: Skin toxicities and immunotherapy.","volume":"19","author":"V Sibaud","year":"2018","journal-title":"Am J Clin Dermatol."},{"issue":"5 Suppl","key":"pone.0255716.ref013","doi-asserted-by":"crossref","first-page":"686","DOI":"10.6004\/jnccn.2015.0204","article-title":"Management of dermatologic toxicities.","volume":"13","author":"ME Lacouture","year":"2015","journal-title":"J Natl Compr Canc Netw."},{"issue":"9","key":"pone.0255716.ref014","doi-asserted-by":"crossref","first-page":"418","DOI":"10.5694\/mja16.00586","article-title":"Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors).","volume":"205","author":"JM Bourke","year":"2016","journal-title":"Med J Aust."},{"issue":"7","key":"pone.0255716.ref015","first-page":"334","article-title":"Economic burden of adverse events associated with immunotherapy and targeted therapy for metastatic melanoma in the elderly.","volume":"11","author":"SR Ghate","year":"2018","journal-title":"Am Health Drug Benefits."},{"issue":"9","key":"pone.0255716.ref016","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/annonc\/mdv182","article-title":"A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors.","volume":"26","author":"TW Chen","year":"2015","journal-title":"Ann Oncol."},{"issue":"10","key":"pone.0255716.ref017","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.","volume":"28","author":"L Khoja","year":"2017","journal-title":"Ann Oncol."},{"key":"pone.0255716.ref018","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-Analysis.","volume":"8","author":"PF Wang","year":"2017","journal-title":"Front Pharmacol."},{"key":"pone.0255716.ref019","doi-asserted-by":"crossref","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"C Xu","year":"2018","journal-title":"BMJ"},{"issue":"8","key":"pone.0255716.ref020","first-page":"658","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"8","author":"PRISMA Group","year":"2010","journal-title":"Int J Surg."},{"key":"pone.0255716.ref021","article-title":"Prevalence of dermatological toxicities in cancer patients submitted to treatment with targeted therapies and immune checkpoint inhibitors: systematic review.","author":"CI Vasques"},{"key":"pone.0255716.ref022","unstructured":"Hamad Bin Khalifa University. Qatar computing research institute: Rayyan. [accessed 20 april 2019]. Available in: https:\/\/rayyan.qcri.org\/welcome."},{"key":"pone.0255716.ref023","unstructured":"Endnote\u2122 basic. \u00a9 Thomson Reuters. [accessed 10 February 2019]. Available in: http:\/\/www.myendnoteweb.com\/."},{"key":"pone.0255716.ref024","unstructured":"Joanna Briggs Institute. The Joanna Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews Checklist for Prevalence Studies. The University of Adelaide: The Joanna Briggs Institute. [accessed 09 february 2019]. Available in: https:\/\/joannabriggs.org\/assets\/docs\/sumari\/ReviewersManual_2017-The-Systematic-Review-of-Prevalence-and-Incidence-Data_v2.pdf; 2017."},{"key":"pone.0255716.ref025","unstructured":"The jamovi project (2021). jamovi (Version 1.6) [Computer Software]. Retrieved from https:\/\/www.jamovi.org"},{"key":"pone.0255716.ref026","first-page":"000","article-title":"A new improved graphical and quantitative method for detecting bias in meta-analysis.","volume":"16","author":"L Fukuya-Kanamori","year":"2018","journal-title":"Int J Evid Based Healthc"},{"issue":"36","key":"pone.0255716.ref027","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1200\/JCO.2008.16.1927","article-title":"Phase I\/II study of ipilimumab for patients with metastatic melanoma.","volume":"26","author":"JS Weber","year":"2008","journal-title":"J Clin Oncol."},{"issue":"7","key":"pone.0255716.ref028","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2008.19.2435","article-title":"Phase I\/II trial of tremelimumab in patients with metastatic melanoma.","volume":"27","author":"LH Camacho","year":"2009","journal-title":"J Clin Oncol."},{"issue":"7","key":"pone.0255716.ref029","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/cncr.24951","article-title":"Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival","volume":"116","author":"GY Ku","year":"2010","journal-title":"Cancer"},{"issue":"26","key":"pone.0255716.ref030","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"C Robert","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0255716.ref031","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: na open-label, phase 2 trial.","volume":"13","author":"K Margolin","year":"2012","journal-title":"Lancet Oncol."},{"key":"pone.0255716.ref032","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1756-9966-32-82","article-title":"Clinical experience with ipilimumab 10 mg\/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme","volume":"32","author":"M Altomonte","year":"2013","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"pone.0255716.ref033","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.","volume":"369","author":"O Hamid","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0255716.ref034","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1634\/theoncologist.2012-0464","article-title":"Ipilimumab for patients with advanced mucosal melanoma.","volume":"18","author":"MA Postow","year":"2013","journal-title":"OncologistJun"},{"issue":"5","key":"pone.0255716.ref035","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.","volume":"31","author":"A Ribas","year":"2013","journal-title":"J Clin Oncol."},{"issue":"1","key":"pone.0255716.ref036","doi-asserted-by":"crossref","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.","volume":"8","author":"CJ Voskens","year":"2013","journal-title":"PLoS One"},{"key":"pone.0255716.ref037","first-page":"7","article-title":"Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma","volume":"13","author":"J Weber","year":"2013","journal-title":"Cancer Immun"},{"issue":"2","key":"pone.0255716.ref038","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"JD Wolchok","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0255716.ref039","first-page":"157","article-title":"Uso de ipilimumab en pacientes con melanoma metast\u00e1tico. Experience en el Hospital M\u00e9dica Sur.","volume":"13","author":"JM Ruiz-Morales","year":"2014","journal-title":"Gazeta Mexicana de Oncologia."},{"issue":"4","key":"pone.0255716.ref040","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"C Robert","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"pone.0255716.ref041","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"MA Postow","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0255716.ref042","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.","volume":"16","author":"A Ribas","year":"2015","journal-title":"Lancet Oncol"},{"issue":"26","key":"pone.0255716.ref043","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"C Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0255716.ref044","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00280-015-2873-x","article-title":"Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma","volume":"76","author":"N Yamazaki","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"pone.0255716.ref045","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s12967-015-0716-5","article-title":"Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.","volume":"13","author":"L Zimmer","year":"2015","journal-title":"J Transl Med."},{"issue":"3","key":"pone.0255716.ref046","doi-asserted-by":"crossref","first-page":"e0118564","DOI":"10.1371\/journal.pone.0118564","article-title":"Phase II DeCOG-study of ipilimumab in pretreated and treatment-na\u00efve patients with metastatic uveal melanoma.","volume":"10","author":"L Zimmer","year":"2015","journal-title":"PLoS One."},{"issue":"19","key":"pone.0255716.ref047","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"AM Eggermont","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0255716.ref048","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"FS Hodi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"pone.0255716.ref049","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"C Hua","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"2","key":"pone.0255716.ref050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study","volume":"44","author":"Y Nakamura","year":"2016","journal-title":"J Dermatol"},{"issue":"5","key":"pone.0255716.ref051","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"PA Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"pone.0255716.ref052","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1684\/ejd.2017.3023","article-title":"Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study.","volume":"27","author":"E Dika","year":"2017","journal-title":"Eur J Dermatol"},{"issue":"1","key":"pone.0255716.ref053","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4143\/crt.2016.024","article-title":"Ipilimumab real-world efficacy and Safety in Korean melanoma patients from the Korean named-patient program cohort","volume":"49","author":"M Jung","year":"2017","journal-title":"Cancer Res Treat"},{"issue":"11","key":"pone.0255716.ref054","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1001\/jamaoncol.2017.1588","article-title":"Nivolumab for patients with advanced melanoma treated beyond progression: Analysis of 2 phase 3 clinical trials","volume":"3","author":"GV Long","year":"2017","journal-title":"JAMA Oncol"},{"issue":"9","key":"pone.0255716.ref055","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S1470-2045(17)30428-X","article-title":"Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): na open-label, phase 1b trial.","volume":"18","author":"GV Long","year":"2017","journal-title":"Lancet Oncol"},{"issue":"19","key":"pone.0255716.ref056","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"J Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0255716.ref057","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00262-017-1989-8","article-title":"The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series","volume":"66","author":"X Wen","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"pone.0255716.ref058","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00280-016-3237-x","article-title":"Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041).","volume":"79","author":"N Yamazaki","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"pone.0255716.ref059","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/cas.13226","article-title":"Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma","volume":"108","author":"N Yamazaki","year":"2017","journal-title":"Cancer Sci"},{"issue":"6","key":"pone.0255716.ref060","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/cas.13241","article-title":"Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study","volume":"108","author":"N Yamazaki","year":"2017","journal-title":"Cancer Sci"},{"issue":"19","key":"pone.0255716.ref061","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"AMM Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0255716.ref062","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: A randomized, controlled, open-label phase III trial.","volume":"36","author":"J Larkin","year":"2018","journal-title":"J Clin Oncol."},{"key":"pone.0255716.ref063","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2018.09.025","article-title":"Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study","volume":"105","author":"K Namikawa","year":"2018","journal-title":"Eur J Cancer"},{"issue":"1","key":"pone.0255716.ref064","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/jamaoncol.2017.2391","article-title":"Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma","volume":"4","author":"AN Shoushtari","year":"2018","journal-title":"JAMA Oncol"},{"key":"pone.0255716.ref065","doi-asserted-by":"crossref","first-page":"E76","DOI":"10.3390\/diagnostics8040076","article-title":"Retrospective side effect profiling of the metastatic melanoma combination therapy ipilimumab-nivolumab using adverse event data.","author":"TG Soldatos","year":"2018","journal-title":"Diagnostics (Basel)."},{"issue":"5","key":"pone.0255716.ref066","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s12094-018-1953-x","article-title":"Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a National consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.","volume":"21","author":"C Gr\u00e1valos","year":"2019","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"pone.0255716.ref067","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.annder.2018.01.047","article-title":"Dermatologic toxicities of immune checkpoint inhibitors.","volume":"145","author":"V Sibaud","year":"2018","journal-title":"Ann Dermatol Venereol."},{"key":"pone.0255716.ref068","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","article-title":"Managing immune checkpoint-blocking antibody side effects.","author":"MA Postow","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"pone.0255716.ref069","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000478081","article-title":"Adverse reactions to biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).","volume":"53","author":"SJE Hwang","year":"2018","journal-title":"Curr Probl Dermatol"},{"issue":"4","key":"pone.0255716.ref070","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","article-title":"Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies.","volume":"28","author":"V Sibaud","year":"2016","journal-title":"Curr Opin Oncol."},{"key":"pone.0255716.ref071","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-3-319-53156-4_8","article-title":"Adverse events in cancer immunotherapy","volume":"995","author":"N Abdel-Wahab","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"pone.0255716.ref072","doi-asserted-by":"crossref","first-page":"579022","DOI":"10.3389\/fimmu.2020.579022","article-title":"Targeting the PD-1\/PD-L1 Axis in Human Vitiligo.","volume":"11","author":"M Willensen","year":"2020","journal-title":"Front. Immunol."},{"issue":"S11","key":"pone.0255716.ref073","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/cncr.30444","article-title":"Immune and molecular correlates in melanoma treated with immune checkpoint blockade","volume":"123","author":"EH Byrne","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"pone.0255716.ref074","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes","volume":"22","author":"M Freeman-Keller","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"pone.0255716.ref075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000485910","article-title":"A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and\/or Complementary Immunomodulatory Effects.","volume":"10","author":"A Utsunomiya","year":"2018","journal-title":"Case Rep Dermatol."},{"issue":"9","key":"pone.0255716.ref076","doi-asserted-by":"crossref","DOI":"10.5070\/D3239036484","article-title":"Erythema multiforme major in a patient with metastatic melanoma treated with ivolumab","volume":"23","author":"S Sundaresan","year":"2017","journal-title":"Dermatology Online Journal"},{"issue":"2","key":"pone.0255716.ref077","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"LK Collins","year":"2017","journal-title":"Curr Probl Cancer"},{"issue":"10","key":"pone.0255716.ref078","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","article-title":"Management of adverse events following treatment with anti-programmed death-1 agents.","volume":"21","author":"JS Weber","year":"2016","journal-title":"Oncologist"},{"issue":"3","key":"pone.0255716.ref079","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1517\/14712598.2016.1141195","article-title":"Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma.","volume":"16","author":"L Spain","year":"2016","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"pone.0255716.ref080","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12254-018-0416-y","article-title":"Management of adverse events related to checkpoint inhibition therapy","volume":"11","author":"JD Rudzki","year":"2018","journal-title":"Magazine of European Medical Oncology"},{"issue":"7","key":"pone.0255716.ref081","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/annonc\/mdw141","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.","volume":"27","author":"J Naidoo","year":"2016","journal-title":"Ann Oncol."},{"issue":"2 Suppl","key":"pone.0255716.ref082","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1188\/17.CJON.S2.45-52","article-title":"Checkpoint inhibitors: Common immune-related adverse events and their management.","volume":"21","author":"R Gordon","year":"2017","journal-title":"Clin J Oncol Nurs."},{"key":"pone.0255716.ref083","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with imune checkpoint blockade: a comprehensive review","volume":"54","author":"JM Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"pone.0255716.ref084","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.2147\/OTT.S127795","article-title":"Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts.","volume":"10","author":"M De Tursi","year":"2017","journal-title":"Onco Targets Ther"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0255716","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T17:37:32Z","timestamp":1628271452000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0255716"}},"subtitle":[],"editor":[{"given":"Gayle E.","family":"Woloschak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,8,6]]},"references-count":84,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0255716","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,6]]}}}